Compare Quest Diagnostics Inc (DGX) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hyatt Hotels Corporation — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | H | |
|---|---|---|
Market Cap | $26.21B | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $202.09 |
52-Week Low | $173.49 | $135.42 |
Enterprise Value | $31.97B | $20.17B |
Dividend Yield | 1.45% | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Hyatt Hotels Corp (H) trades at $178.25, up 4.8% over 24 hours, near its 52-week high of $206.86. The stock shows a bearish technical signal despite recent earnings beats, with Q2 2026 EPS of $1.12 surpassing the $0.913 estimate. Fundamentals reveal a high P/E ratio of 213.14 and thin net income margin of 1.1%, though revenue grew to $7.10B in 2025. Analyst consensus is a 'Hold' with a $199.55 price target, while recent news highlights valuation concerns amid fee growth and RevPAR gains.
Outlook is mixed: strong fee growth and a record pipeline support expansion, but high valuation, project delays, and debt pose risks. The stock offers potential from operational momentum, yet investors face headwinds from regional weakness and rich multiples. Net cash flow turned negative in 2025, underscoring financial pressure despite EBITDA growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
